Category Archives: pegylation

The next stop for PEGylated protein drugs: Biosimilar

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analog filgrastim. It serves to stimulate the level of white blood cells. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim … Continue reading

Posted in Biologic, Biosimilar, Blogs, cancer, chemotherapy, pegylation | Leave a comment

PEG reagents for surface functionalization of carbon nanotubes and graphenes

PEGylated pyrene derivatives can be used for the surface functionalization of carbon nanotubes and graphenes via the strong (close to irreversible) pi-pi stacking between the pyrene and the aromatic rings on single wall and multi-walled carbon nanotubes. Pyrene is conjugated … Continue reading

Posted in Carbon nanotubes, graphene, pegylation | Tagged | Leave a comment

FDA approved PEGylated drug

To date, eleven PEGylated proteins, antibody fragments, oligonucleotides, and small molecules have been approved by FDA are on the market, including PEGylated bovine adenosine deaminase: pegademase bovine (Adagen); and PEGylated l-asparaginase: pegaspargase (Oncaspar); PEGylated products of interferon-alpha (IFN-alpha): peginterferon-2b (PegIntron) … Continue reading

Posted in Blogs, PEGylated Products on Market, pegylation, PEGylation Success Stories | Tagged , , , | 1 Comment

Can a PEGylated protein be ever considered a Biosimilar drug?

In March 2015, the FDA approved the first biosimilar drug for use in the United States. The drug called Zarxio, produced by Sandoz, is used to help prevent infections in cancer patients receiving chemotherapy, and it is a biosimilar alternative … Continue reading

Posted in Biologic, Biosimilar, Blogs, cancer, chemotherapy, pegylation, PEGylation Reagents | Tagged , , , , , , | Leave a comment